Background: Depression is a widely recognized neuropsychiatric condition that often occurs as a comorbidity with various medical illnesses, including neurodegenerative disorders like Parkinson's disease (PD). This study aimed to identify the age of onset and underlying disease characteristics associated with patients exhibiting mild to moderate depression comorbid with PD.

Methods: This retrospective case-control study included 114 elderly patients (age ≥65 years) diagnosed with Parkinson's disease. The patients were divided into two groups: the non-depressed group (n = 65) and the mild to moderate depression group (n = 49). Patients' emotional and affective symptoms, cognitive function, and clinical characteristics were assessed using standardized scales. Statistical analyses, including chi-square tests, Wilcoxon rank-sum tests, and logistic regression analysis, were performed to evaluate associations and correlations between the variables of interest.

Results: Our findings revealed that patients in the mild to moderate depression group exhibited a significantly lower onset age of PD (52.33 ± 3.87 years) compared to the non-depressed group (59.27 ± 3.62 years, p < 0.001). Furthermore, patients with mild to moderate depression showed significantly higher scores in mood and affective symptoms measures, including the Hamilton Anxiety Scale (HAM-A) (p < 0.001) and Apathy Scale (p < 0.001). Additionally, the duration of Parkinson's disease was significantly longer in the mild to moderate depression group (6.78 ± 2.01 years) compared to the non-depressed group (3.45 ± 1.52 years, p < 0.001). Similarly, patients in the mild to moderate depression group exhibited significantly poorer performance on the Mini-Mental State Examination (MMSE) (p < 0.001), Montreal Cognitive Assessment (MoCA) (p = 0.025), verbal fluency (p < 0.001), and Trail Making Test (p = 0.005). Additionally, correlation and logistic regression analysis revealed associations and predictive value of these variables with the presence of mild to moderate depression in Parkinson's disease.

Conclusion: The study highlights the complex interaction of age and underlying disease characteristics in patients with mild to moderate depression comorbid with Parkinson's disease. Early recognition and tailored management of depressive symptoms, mood and affective disturbances, cognitive impairment, and disease-specific characteristics are crucial for optimizing patient care and improving outcomes in individuals with Parkinson's disease. These findings underscore the need for a comprehensive, patient-centered approach that considers the diverse interaction of demographic, clinical, and cognitive variables.

Download full-text PDF

Source
http://dx.doi.org/10.62641/aep.v53i2.1702DOI Listing

Publication Analysis

Top Keywords

mild moderate
36
moderate depression
36
parkinson's disease
24
patients mild
20
depression group
16
underlying disease
12
disease characteristics
12
depression comorbid
12
non-depressed group
12
depression
10

Similar Publications

Vestibular deficits are common and debilitating, and many patients struggle with dynamic balance, even after treatment with standard rehabilitation techniques. The objective of this study was to measure changes in computerized dynamic posturography sensory ratio information after computerized vestibular retraining therapy (CVRT). This prospective, single-group, interventional study enrolled adult participants with stable, unilateral vestibular deficits.

View Article and Find Full Text PDF

Few studies explore the burden of mild-to-moderate atopic dermatitis (AD). We aimed to investigate disease burden in mild-to-moderate AD using real-world data from adults with AD and their physicians in the United States. Data were drawn from the Adelphi Real World AD Disease Specific Programme™, a cross-sectional survey of physicians and their patients with AD in real-world clinical practice in the US from November 2014 to February 2015.

View Article and Find Full Text PDF

Eye diseases are widespread all over the world and, if left untreated, can lead to blindness. The use of 0.05% cyclosporine A (CsA) solution for the treatment of dry eye causes a decrease in discomfort and pain and improves objective measures such as tear film breakdown time, Schirmer test results and Oxford scale scores due to its anti-inflammatory and immunomodulatory properties that contribute to improved tear film stability and tear production.

View Article and Find Full Text PDF

Prcis: In this retrospective cohort study, the 1-year cumulative probability of failure was comparable, achieving 52.20% in the phacoemulsification-iStent inject W (phaco/iStent) group and 47.80% in the phacoemulsification-micropulse transscleral laser therapy (phaco/MPTLT) group (P=0.

View Article and Find Full Text PDF

Objective: Ulcerative colitis (UC) is a chronic immune-mediated disease requiring ongoing treatment to maintain remission. This report presents the 2-year safety outcomes of mirikizumab, a humanized immunoglobulin G4 anti-interleukin-23p19 monoclonal antibody, in moderately to severely active UC from Phase 3 studies LUCENT-1 (NCT03518086), LUCENT-2 (NCT03524092), and LUCENT-3 (NCT03519945).

Methods: Patients who underwent induction (LUCENT-1) and maintenance (LUCENT-2), and entered long-term maintenance (LUCENT-3) were assessed in 2 cohorts: induction responders and extended-induction responders.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!